Barbara Dalton, Ph.D.Director
Barbara J. Dalton, Ph.D. joined Pfizer in 2007 to manage the Pfizer Ventures Investments (PVI) team within the Worldwide Business Development organization. Dr. Dalton has 24 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in direct and indirect healthcare investing. She has had management responsibility for over 100 diverse company investments and 30 fund investments and in both the US and Europe. PVI has invested in over 50 companies pursuing products, technologies and services relevant to all aspects of Pfizer’s business, since inception in 2004. Barbara currently represents PVI’s investments in Ablexis, The Accelerator NYC, Cydan, Imara, Ixchelsis, Levicept, Lodo Therapeutics, Morphic Therapeutics, Petra Pharma and Rhythm Pharmaceuticals.

Dr. Dalton began her pharmaceutical career as a research scientist in Immunology at SmithKline and French Laboratories in 1983 and joined their venture capital group, S.R. One, Limited ten years later. Dr. Dalton was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner. Dr. Dalton has been on the board of academic groups, not-for-profit foundations and industry organizations in her role as a member of the BioPharma ecosystem in both the Philadelphia and New York communities. She, along with Brenda Gavin, were instrumental in the creation of the corporate subgroup of the National Venture Capital Association. She is currently the Chairman of the Healthcare Sector of the Partnership Fund for New York City.

Dr. Dalton is a graduate of Penn State and received her Ph.D. in Microbiology and Immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School).

David MottDirector
David Mott joined New Enterprise Associates in September 2008 as a General Partner and leads the healthcare investing practice, which typically comprises roughly one-third of each fund, or $1.1 billion of healthcare venture investments every two-to-three years. NEA is a leading investor across all healthcare sub-sectors, including biopharma, medical technology, and healthcare services, and invests across all stages and geographies. Mr. Mott’s personal investing practice is primarily focused on biopharmaceutical investments. Prior to joining NEA, Mr. Mott was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. Mr. Mott joined MedImmune in 1992 and served in various roles including, from October 2000 through June 2008, president and chief executive officer, and previously chief financial officer, and president and chief operating officer. He led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. At the time of his departure in July 2008, MedImmune had annual revenues in excess of $1.5 billion, annual R&D in excess of $650 million and approximately 3,000 employees. Prior to joining MedImmune, Mr. Mott was a Vice President in Health Care Investment Banking at Smith Barney, Harris Upham & Co., Inc. where he focused on public and private equity and debt financings as well as mergers and acquisitions. He received a bachelor of arts degree in economics and government from Dartmouth College.

Mr. Mott is currently Chairman of 3-V Biosciences, Adaptimmune (NASDAQ: ADAP), Ardelyx (NASDAQ: ARDX), Cydan, Epizyme (NASDAQ: EPZM), Imara, Mersana (NASDAQ: MRSN), and TESARO (NASDAQ: TSRO), and is a director of Clementia, Complexa, Nightstar, and Xtuit.

Gilles Nobécourt Director
Gilles Nobécourt joined Edmond de Rothschild Investment Partners in 2002. Previously, he has been Social Advisor in the French Senate (1981-1982), Chief of Staff to the President of Languedoc Roussillon Regional Council (1982), Advisor to the French Minister for Industry and Research (1983), and subsequently Advisor to the French Prime Minister (1984-1986). Field Officer for the United Nations High Commissioner for Refugees in Africa and Central America until 1989, he then joined Rhône-Poulenc Group as Vice President, Public Affairs. In 1992, Gilles was appointed Vice President, assistant to the Chairman and CEO of Rhône-Poulenc Rorer, the pharmaceutical affiliate of Rhône-Poulenc. He later became a founding member of RPR Gencell, the biotechnology division of Rhône-Poulenc Rorer. Initially General Manager for Europe, he was subsequently deputy General Manager of the Division based in San Francisco until 1999. Appointed General Manager of a commercial subsidiary in Mexico City, he ultimately left Aventis and joined Russell Reynolds & Associates as consultant dedicated to pharmaceutical and biotechnology companies until 2002.

He has been a Partner at Edmond de Rothschild Investment Partners since. In addition to Complexa, Gilles is a director of Genkyotex, Complix, Gamamabs, Inotrem, Fondation Ophtalmologique Adolphe de Rothschild and Managing Partner of EdRIP.

Graduated from the Paris Institute for Political Sciences (‘Sciences Po Paris’) in 1980, Gilles holds also a Master degree in applied economics and a certificate from the Stanford Global School of Business.

Kenji Harada, Ph.D.Director
Dr. Harada, Ph.D. has more than 20 years of experience in evaluating medical drug candidates, scientific technology platforms and intellectual property portfolios. In 2004, he joined JAFCO, the largest venture capital firm in Japan, working for the life science investment group as a group leader. In this role, he evaluates US or Japan-based biotech companies for potential investment opportunities, several of which have successfully gone on to become public companies or the subject of significant acquisitions. Prior to JAFCO, Dr. Harada held positions of increasing responsibility within the medical drug and devices division of Toray Industries, Inc., a leading Japanese chemical and fiber company, most recently as manager for collaborative research agreements with a number of leading Japanese academic institutes and biotechnology companies. In addition to his board position at Complexa, Dr. Harada also served on the board of TRACON Pharmaceuticals and Eleven Biotherapeutics. He is an immunologist by training, earning his PhD in pharmacology at the University of Tokyo.
Sara Nayeem, M.D.Director
Sara Nayeem, M.D. is a Partner at New Enterprise Associates (NEA). Dr. Nayeem joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. Prior to joining NEA, she was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, Dr. Nayeem worked as an Investment Banking Analyst at Morgan Stanley. Dr. Nayeem concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.

In addition to Complexa, Dr. Nayeem serves on the boards of Mersana (MRSN), Cydan and Imara, and as a board observer for Clementia, Millendo, and NightstaRx. She previously served on the board of Vtesse (acquired by Sucampo) and as a board observer for Tesaro (TSRO), Ziarco (acquired by Novartis), Loxo Oncology (LOXO), Omthera (acquired by AstraZeneca), Epizyme (EPZM), and Zyngenia. She has also been involved in NEA’s investments in Prosensa (acquired by BioMarin), Proteostasis (PTI), 3-V Biosciences, XTuit, and Edimer. She also serves on the board of BioHealth Innovation Management. She has been selected three times as one of GrowthCap’s Top 40 Under 40 Growth Investors.

Josh TarnoffDirector, President and Chief Executive Officer
Mr. Tarnoff joined Complexa in 2011 as Director, President and Chief Executive Officer. Mr. Tarnoff brings 30 years of pharmaceutical experience to his leadership of Complexa. He has built and led business units within large pharma and developed multiple early stage start-ups. His most recent roles include serving as CEO of JDP Therapeutics, CEO of Houston Pharma (and its subsidiary Potomac Pharma), and CCO at ViroPharma. One of his many roles within large pharma was leading a $1.5 billion U.S. business unit at AstraZeneca. He is a recognized industry leader for his expertise in creating successful management teams, building start-up companies, strategic planning and corporate development. Mr. Tarnoff also has a strong record of a series of capital raises. With a career that advanced within the executive ranks of the commercial and operations side of the industry, he brings a unique set of skills that blend clinical and business development activities. Mr. Tarnoff received a bachelor’s degree in Biology from LaSalle University. He is also currently a board member of several early stage healthcare companies.
I. Wistar MorrisDirector
Mr. I. Wistar Morris joined the board in 2012. He is Senior Investment Consultant to Pennsylvania Trust. In April 2011 he retired from Boenning & Scattergood, an Investment Securities firm, where he served as a Director and Investment Advisor for 20 years. Prior to this, Mr. Morris founded the Morris Investment Management Company and held the roles of President and Chairman. Mr. Morris was also Executive Vice President with the investment management firm Hopper Soliday & Co., spending 15 years there. Mr. Morris has been on the boards of 20 public and private companies.

In the non-profit world, he currently serves as trustee to The Academy of Natural, Lankenau Medical Center, Lankenau Institute of Medical Research, the Mount Desert Island Biological Laboratory, and the Wistar Institute. He is the Founder and CEO of The Cotswold Foundation and is the author of Adventures in Investing, which describes his career in the investment business. Mr. Morris received a bachelor’s degree in Chemistry from Cornell University, an M.B.A. from the Harvard Business School, and holds the CFA designation from the CFA Institute.